WO1998019679A1 - Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis - Google Patents
Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis Download PDFInfo
- Publication number
- WO1998019679A1 WO1998019679A1 PCT/GB1997/003036 GB9703036W WO9819679A1 WO 1998019679 A1 WO1998019679 A1 WO 1998019679A1 GB 9703036 W GB9703036 W GB 9703036W WO 9819679 A1 WO9819679 A1 WO 9819679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- cpt
- cftr
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Definitions
- the present invention relates to the use of derivatives of theophylline for the preparation of medicaments suitable for the treatment of cystic fibrosis.
- it relates to the use of 8-cyclopentyl theophylline (CPT) for the preparation of medicaments for the treatment of cystic fibrosis.
- CPT 8-cyclopentyl theophylline
- Such medicaments may be administered orally or directly to the lung, for example, in the form of an aerosol.
- Cystic fibrosis is one of the most common lethal inherited disorders occurring in Caucasian populations. It is characterized as an exocrinopathy involving disturbances in mucin secretion, i.e. resulting in an altered composition of epithelial cell mucous secretions, and in electrolyte transport, in particular chloride transport. These manifestations of the disorder are caused by mutations in the cystic fibrosis (CF) gene, which encodes the cystic fibrosis transmembrane conductance regulator protein (CFTR) .
- CF cystic fibrosis
- R 1 and R 2 are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms, provided that R 1 and R 2 are not both propyl groups, for the manufacture of a medicament for the treatment of cystic fibrosis .
- the compound of formula (1) used for the manufacture of a medicament is 8-cyclopentyl-theophylline, where R 1 and R 2 in formula (1) are both methyl groups.
- R 1 and R 2 are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms, provided R 1 and R 2 are not both propyl groups, together with a pharmaceutically acceptable carrier therefor.
- R 1 and R 2 are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms, provided that R 1 and R 2 are not both methyl groups or propyl groups .
- Figure 1 shows the structure of IBMX, DMPX and CPT
- Figure 2 shows the effects of different concentrations of CPT and DMPX on mucin secretion from normal rat submandibular acini .
- Figure 3 shows the effect of CPT on CFTR antibody inhibited ⁇ -adrenergic stimulation of mucin secretion.
- the medicament or pharmaceutical formulation according to the invention which contains a compound of formula (1) may be presented in a form suitable for oral administration in a pharmaceutical vehicle convenient for that administrative route.
- the medicament may be presented as tablets, capsules, ingestible liquid or a powder preparation.
- Such formulations can include pharmaceutically acceptable carriers known to those skilled in the art.
- Formulations suitable for oral administration further include lozenges, pastilles, aerosols and mouthwashes .
- the medicament or pharmaceutical formulation may be administered direct to the lung via the nasal passage.
- Formulations suitable for nasal administration where the carrier is a solid, include powders. Where the carrier is a liquid the formulation can be administered as a nasal spray or aerosol, or as drops.
- the medicament may be presented in a formulation suitable for parenteral or intravenous administration, such as aqueous or non-aqueous sterile injectable solutions. Such solutions may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient.
- the formulation for parenteral administration may be presented as an aqueous or non aqueous sterile suspension which may include suspending agents and thickening agents.
- a therapeutically effective dose may typically comprise administering the active ingredient at the rate of 0.001 to 25 mg/kg body weight per day, and more preferably at a rate of from 0.01 to 0.5 mg/kg/day.
- the medicament may contain from 0.001 to 0.01% w/w of the active ingredient.
- CPT (8-cyclopentyl theophylline) may be prepared by mixing 5, 6-diamino-l , 3 -dimethyl uracil with 1 - 1.25M equivalent of cyclopentanecarboxylic acid followed by heating at 120 - 200°C for 1 to 4 hours to give the solid amide. The solid amide is then powdered and heated with 5 -
- R 1 and R 2 are the same or different and each represents an alkyl group having from 1 to 5 carbon atoms provided that R 1 and R 2 are not both propyl groups .
- KLH keyhole limpet haemocyanin
- the peptide sequence was searched for in the Swissprot database (BLASTP and FASTA3_T, 1997) and only CFTR was found to contain a perfect match.
- Antisera were prepared as described in C.
- acini were pulse-chase labelled with [ 3 H] - glucosamine and suspended in TES-buffered saline (lOmM TES,
- acini suspension 800 ⁇ l of either lOmM TES, pH 7.4 (swollen) or TES-buffered saline (unswollen) , each containing 5mM ATP and antibody (approx lmg IgG/ml) was added for 1.5 min at room temperature, followed by washing and resuspension in Krebs-Henseleit bicarbonate (KHB) buffer containing 20mg/ml BSA. Following a 15 min recovery incubation at 37°C in KHB buffer, acini were washed and incubated under experimental conditions at 37°C.
- KHB Krebs-Henseleit bicarbonate
- IBMX 3-isobutylmethylxanthine
- cyclic AMP content Aliquots of acini suspensions (0.25ml) were added to an equal volume of ice cold trichloroacetic acid (20%) , extracted and assayed using a specific radioimmunoassay kit for cyclic AMP (Amersham) .
- Fig. 1 shows the structure of CPT which is more selective for the Al receptor, and DMPX (3 , 7-dimethyl-1-propargylxanthine) which is more selective for the A2 receptor compared to that of IBMX.
- Fig.2 shows the effects of different concentrations of CPT and DMPX on mucin secretion from normal rat submandibular acini, isolated as described in the Methods.
- DMPX was the more effective stimulator, and at ImM increased mucin secretion to a similar degree to that obtained with isoproterenol or IBMX (Table 2) .
- CPT was much less potent and at ImM gave a small but significant increase above basal levels.
- Doses of CPT close to the K ⁇ for Al adenosine receptor antagonism did not stimulate mucin secretion (lOnM CPT; 104% basal) .
- the data indicate that the effect of CPT in increasing mucin secretion is unlikely to be related to Al receptor antagonism.
- IBMX was shown to correct defective CFTR function at a maximum concentration which did not significantly stimulate mucin secretion. Thus a concentration of CPT giving marginal stimulation (ImM) and a similar concentration of DMPX were tested for correction of defective CFTR function. Table 1 shows that the A2 adenosine receptor antagonist, DMPX did not correct defective ⁇ -adrenergic stimulation of mucin secretion in CFTR antibody containing cells. As shown previously, mucin secretion in response to isoproterenol from cells containing CFTR antibody, introduced by hypotonic swelling as described in the Methods, was significantly decreased compared to cells swollen in an equivalent amount of non-immune IgG.
- Fig. 3 shows that the Al receptor antagonist CPT corrected the defective isoproterenol -stimulated mucin secretion in submandibular cells containing CFTR antibody, at mM concentrations.
- the actions of CPT in increasing the CFTR antibody-inhibited response were almost as effective as that of mM cpt-cyclic AMP (8- (4-chlorophenylthio) -cyclic AMP) which has been previously shown to restore secretory responsiveness to approx: 75% of that seen in cells containing similar amount of non-immune IgG.
- CPT at high concentration, corrected the CFTR antibody-inhibited mucin secretory response suggesting that a mechanism other than Al receptor antagonism was operating.
- CPT is a less effective stimulator of mucin secretion than IBMX; but it induces greater increases in cyclic AMP.
- DMPX which did not correct CFTR function, increases mucin secretion to a greater degree than CPT (Fig. 2) and induces increases in cyclic AMP greater than those induced by isoproterenol alone
- IBMX also acts as a non-selective cyclic nucleotide phosphodiesterase inhibitor which increases cyclic AMP levels in submandibular acini and potentiates the cyclic AMP rise induced by isoproterenol. Furthermore, since the correction of CFTR-mediated mucin secretion was mimicked by cpt-cyclic AMP, it was postulated that excessive increase in cellular cyclic AMP could be a mechanism by which CFTR activity is restored. This hypothesis was tested by investigating the effects of the adenosine receptor antagonist on cyclic AMP levels in the presence or absence of isoproterenol. It is clear from the results in Table 3 that CFTR function could be corrected without potentiating the isoproterenol induced cyclic AMP rise although CPT increased cyclic AMP levels alone.
- Mucin release was measured at 30 min and cyclic AMP at
- a solution suitable for use as nasal drops is prepared by dissolving CPT (0.2 mg/ml) in isotonic saline containing hypromellose, with the optional addition of a suitable buffer.
- a solution suitable for intravenous injection is prepared by dissolving CPT (0.2 mg/ml) in isotonic saline containing sodium EDTA, with the optional addition of a suitable buffer.
- Example 5 Aerosol Formulation A solution suitable for aerosolisation into the lungs is prepared by mixing CPT (0.2 mg/ml) with oleic acid and priolene, which mixture can then be delivered to the lungs using the following propellents - 11 (trichlorofluoromethane) 12 (dichloro difluoromethane) .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002270355A CA2270355A1 (en) | 1996-11-05 | 1997-11-05 | Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis |
AU48751/97A AU4875197A (en) | 1996-11-05 | 1997-11-05 | Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis |
EP97911336A EP0973521A1 (en) | 1996-11-05 | 1997-11-05 | Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9622981.0 | 1996-11-05 | ||
GBGB9622981.0A GB9622981D0 (en) | 1996-11-05 | 1996-11-05 | Cystic fibrosis medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998019679A1 true WO1998019679A1 (en) | 1998-05-14 |
Family
ID=10802439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/003036 WO1998019679A1 (en) | 1996-11-05 | 1997-11-05 | Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0973521A1 (en) |
AU (1) | AU4875197A (en) |
CA (1) | CA2270355A1 (en) |
GB (1) | GB9622981D0 (en) |
WO (1) | WO1998019679A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1448203A1 (en) * | 2001-10-26 | 2004-08-25 | Sciclone Pharmaceuticals, Inc. | Pharmaceutical formulations comprising substituted xanthine compounds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0322206A2 (en) * | 1987-12-21 | 1989-06-28 | Her Majesty In Right Of Canada As Represented By The Minister Of National Defence | Compositions and methods for improving cold tolerance in animals and humans |
WO1995010282A1 (en) * | 1993-10-13 | 1995-04-20 | Mcgill University | Use of phosphatase inhibitors for the manufacture of a medicament in the treatment of channel related diseases |
-
1996
- 1996-11-05 GB GBGB9622981.0A patent/GB9622981D0/en active Pending
-
1997
- 1997-11-05 CA CA002270355A patent/CA2270355A1/en not_active Abandoned
- 1997-11-05 EP EP97911336A patent/EP0973521A1/en not_active Withdrawn
- 1997-11-05 WO PCT/GB1997/003036 patent/WO1998019679A1/en not_active Application Discontinuation
- 1997-11-05 AU AU48751/97A patent/AU4875197A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0322206A2 (en) * | 1987-12-21 | 1989-06-28 | Her Majesty In Right Of Canada As Represented By The Minister Of National Defence | Compositions and methods for improving cold tolerance in animals and humans |
WO1995010282A1 (en) * | 1993-10-13 | 1995-04-20 | Mcgill University | Use of phosphatase inhibitors for the manufacture of a medicament in the treatment of channel related diseases |
Non-Patent Citations (5)
Title |
---|
COHEN B E ET AL: "1,3-Dipropyl-8-cyclopentylxanthine and Other Xanthines Differentially Bind to the Wild-Type and.DELTA.F508 Mutant First Nucleotide Binding Fold (NBF-1) Domains of the Cystic Fibrosis Transmembrane Conductance Regulator", BIOCHEMISTRY (BICHAW,00062960);97; VOL.36 (21); PP.6455-6461, NIH;LABORATORY OF CELL BIOLOGY AND GENETICS NIDDK; BETHESDA; 20892; MD; USA (US), XP002055502 * |
EIDELMAN O ET AL: "A1 ADENOSINE-RECEPTOR ANTAGONISTS ACTIVATE CHLORIDE EFFLUX FROM CYSTIC FIBROSIS CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 89, no. 12, 15 June 1992 (1992-06-15), pages 5562 - 5566, XP000565692 * |
ERICKSON R H ET AL: "1,3,8,-TRISUBSTITUTED XANTHINES. EFFECTS OF SUBSTITUTTION PATTERN UPON ADENOSINE RECEPTOR A1/A2 AFFINITY", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 4, 1 April 1991 (1991-04-01), pages 1431 - 1435, XP000574702 * |
JACOBSON K A ET AL: "STIMULATION BY ALKYLXANTHINES OF CHLORIDE EFFLUX IN CFPAC-1 CELLS DOES NOT INVOLVE A1 ADENOSINE RECEPTORS", BIOCHEMISTRY, vol. 34, no. 28, 18 July 1995 (1995-07-18), pages 9088 - 9094, XP000565691 * |
SUZUKI F ET AL: "Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure", J. MED. CHEM. (JMCMAR,00222623);92; VOL.35 (16); PP.3066-75, KYOWA HAKKO KOGYO CO., LTD.;PHARM. RES. LAB.; NAGAIZUMI; 411; JAPAN (JP), XP002055503 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1448203A1 (en) * | 2001-10-26 | 2004-08-25 | Sciclone Pharmaceuticals, Inc. | Pharmaceutical formulations comprising substituted xanthine compounds |
EP1448203A4 (en) * | 2001-10-26 | 2010-05-26 | Sciclone Pharmaceuticals Inc | Pharmaceutical formulations comprising substituted xanthine compounds |
Also Published As
Publication number | Publication date |
---|---|
GB9622981D0 (en) | 1997-01-08 |
AU4875197A (en) | 1998-05-29 |
CA2270355A1 (en) | 1998-05-14 |
EP0973521A1 (en) | 2000-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090062301A1 (en) | Pharmaceutical combination composition comprising at least one pkc inhibitor and at least one ja k3 kinase inhibitor for treating autoimmune disorders | |
JP2001513568A (en) | Use of uridine 5'-diphosphate and its analogs for treating lung disease | |
JP2002537340A (en) | How to treat mitochondrial disease | |
WO2012107364A1 (en) | Novel composition for the treatment of cystic fibrosis | |
CA2383351C (en) | Xanthine derivatives as selective antagonists of a2b adenosine receptors | |
US11560375B2 (en) | Composition and method for treating metabolic disorders | |
US6599907B1 (en) | Cystic fibrosis medicaments | |
US5366977A (en) | Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners | |
EP0686155B1 (en) | Xanthine derivatives as adenosine a1 receptor antagonists | |
EP1411967B1 (en) | Blocking peptide for inflammatory cell secretion | |
WO1998019679A1 (en) | Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis | |
Diaz-Munoz et al. | Purine molecules as hypnogenic factors role of adenosine, ATP, and caffeine | |
AU2002322475A1 (en) | Blocking peptide for inflammatory cell secretion | |
US6806270B2 (en) | Selective antagonists of A2B adenosine receptors | |
WO1996003134A1 (en) | Treatment of diarrhea with 2-substituted adenosine derivatives | |
JP4688681B2 (en) | Neutropenia inhibitor | |
EP1893208B1 (en) | Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder | |
US20040214789A1 (en) | Therapeutics | |
Fischmeister et al. | Hormonal and non-hormonal regulation of Ca 2+ current and adenylate cyclase in cardiac cells | |
Díaz-Muñoz et al. | Purine Molecules as Hypnogenic Factors Role of Adenosine, ATP, and |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: PAT. BUL. 19/98 UNDER (81) ADD "EP (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,SE)" |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997911336 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2270355 Country of ref document: CA Ref country code: CA Ref document number: 2270355 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09297322 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997911336 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997911336 Country of ref document: EP |